All In Biotech

Drug Trial Radar · NCT00006734

Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor

Trial of Chemotherapy Intensification Through Compression in Ewing's Sarcoma and Related Tumors

Last checked: Nov 20, 2026Latest source record: Aug 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 587 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

587

Actual

Start

May 2001

Primary completion

Aug 2006

Study completion Jun 30, 2023

Sponsor

Lead sponsor
Children's Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); SWOG Cancer Research Network
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 0 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which chemotherapy regimen combined with radiation therapy and/or surgery is more effective in treating Ewing's sarcoma or primitive neuroectodermal tumor. PURPOSE: Randomized phase III trial to compare the effectiveness of different chemotherapy regimens combined with radiation therapy and/or surgery in treating patients who have Ewing's sarcoma or primitive neuroectodermal tumor.

Conditions

  • Sarcoma

Interventions

  • filgrastimBiological

    Given IV

  • cyclophosphamideDrug

    Given IV

  • doxorubicin hydrochlorideDrug

    Given IV

  • etoposideDrug

    Given IV

  • ifosfamideDrug

    Given IV

  • vincristine sulfateDrug

    Given IV

  • adjuvant therapyProcedure

  • conventional surgeryProcedure

  • neoadjuvant therapyProcedure

  • brachytherapyRadiation

  • radiation therapyRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survivalTime frame: Time from study entry until disease progression, death without progression of disease, occurrence of a second malignant neoplasm or last follow-up, whichever comes first, assessed up to 5 years

Locations

239 sites in 7 countries. Site status is shown where the registry gives one.

  • Comprehensive Cancer Center at University of Alabama at Birmingham

    Birmingham, Alabama

  • University of South Alabama Cancer Research Institute

    Mobile, Alabama

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Arizona Cancer Center at University of Arizona Health Sciences Center

    Tucson, Arizona

  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Southern California Permanente Medical Group

    Downey, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Rebecca and John Moores UCSD Cancer Center

    La Jolla, California

  • Loma Linda University Cancer Institute at Loma Linda University Medical Center

    Loma Linda, California

  • Jonathan Jaques Children's Cancer Center at Miller Children's Hospital

    Long Beach, California

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center

    Los Angeles, California

  • Jonsson Comprehensive Cancer Center at UCLA

    Los Angeles, California

  • Children's Hospital Central California

    Madera, California

  • Children's Hospital and Research Center at Oakland

    Oakland, California

  • Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center

    Orange, California

  • Children's Hospital of Orange County

    Orange, California

  • Lucile Packard Children's Hospital at Stanford University Medical Center

    Palo Alto, California

  • Sutter Cancer Center

    Sacramento, California

  • University of California Davis Cancer Center

    Sacramento, California

  • Kaiser Permanente Medical Center - Sacramento

    Sacramento, California

  • Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego

    San Diego, California

  • Children's Hospital and Health Center - San Diego

    San Diego, California

  • UCSF Comprehensive Cancer Center

    San Francisco, California

  • Santa Barbara Cottage Hospital

    Santa Barbara, California

  • Kaiser Permanente Medical Center - Santa Clara

    Santa Clara, California

  • General Robert Huyser Cancer Center at David Grant Medical Center

    Travis Air Force Base, California

  • Children's Hospital Cancer Center

    Denver, Colorado

  • Presbyterian - St. Luke's Medical Center

    Denver, Colorado

  • Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center

    Farmington, Connecticut

  • Yale Comprehensive Cancer Center

    New Haven, Connecticut

  • Alfred I. duPont Hospital for Children

    Wilmington, Delaware

  • Lombardi Cancer Center at Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Broward General Medical Center

    Fort Lauderdale, Florida

  • Children's Hospital of Southwest Florida

    Fort Myers, Florida

  • University of Florida Shands Cancer Center

    Gainesville, Florida

  • Joe DiMaggio Children's Hospital at Memorial

    Hollywood, Florida

  • Nemours Children's Clinic

    Jacksonville, Florida

  • Jackson Memorial Hospital

    Miami, Florida

Showing 40 of 239 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.